AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18004709 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 16172147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 4 weeks (group I, n = 42)
Number of subjects: 130
Study 16172147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 6 weeks (group II, n = 51)
Number of subjects: 130
Study 16172147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 600 mg testosterone decanoate every 6 weeks (group III, n = 37)
Number of subjects: 130
Study 14669843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate (E2V)
Number of subjects: 49
Study 14669843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate (E2V) + 3 mg dienogest (DNG)
Number of subjects: 49
Study 14669843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11079281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of education on the use of a metered-dose inhaler (MDI)-spacer device
Number of subjects: 83
Study 8646142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitary suppression with a luteinising hormone releasing hormone analogue followed by low dose ovulation induction and luteal phase progesterone
Number of subjects: 106
Study 1330192 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasound (US)
Number of subjects: 22
Study 1330192 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex sonography (DS)
Number of subjects: 22
Study 1330192 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 22
Study 3872000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 20
Study 3872000 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study 30987963 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip transcatheter mitral valve repair
Number of subjects: 330
Study 30987963 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 330
Study 30561402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based preoperative chemoradiotherapy
Number of subjects: 0
Study 30561402 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation alone
Number of subjects: 0
Study 27579261 — intervention group
Group type: EXPERIMENTAL
Intervention: Albanian's Health Promoting Schools Model (Albanian's HPSM) intervention for 6 weeks
Number of subjects: 120
Study 27579261 — intervention group
Group type: EXPERIMENTAL
Intervention: Albanian's Health Promoting Schools Model (Albanian's HPSM) intervention
Number of subjects: 120
Study 24754328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prenatal probiotic (Florajen3) taken once daily
Number of subjects: 20
Study 24754328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 20
Study 22548396 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer-dye laser (EDL) (630 nm)
Number of subjects: 25
Study 22548396 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-halide lamp (MHL) (600 to 740 nm)
Number of subjects: 25
Study 21173319 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor tanning use
Number of subjects: 2869
Study 21173319 — intervention group
Group type: COMPARATOR
Intervention: Demographic and lifestyle factors
Number of subjects: 2869
Study 21173319 — intervention group
Group type: COMPARATOR
Intervention: Skin cancer knowledge and attitudes
Number of subjects: 2869
Study 21173319 — intervention group
Group type: COMPARATOR
Intervention: Skin cancer knowledge and perceived risk
Number of subjects: 2869
Study 16516188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative task
Number of subjects: 2
Study 16516188 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive task
Number of subjects: 2
Study 16516188 — intervention group
Group type: COMPARATOR
Intervention: Isolation (not explicitly mentioned as a control)
Number of subjects: 2
Study 16376767 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of spontaneous echocontrast (SEC) in the left atrial appendage (LAA)
Number of subjects: 47
Study 16376767 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA wall velocity
Number of subjects: 47
Study 16376767 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA flow velocity
Number of subjects: 47
Study 16376767 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA tissue intensity
Number of subjects: 47
Study 12086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times daily
Number of subjects: 682
Study 12086760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study 9862412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration 5 min prior to word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration immediately before word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration immediately following word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration 10 min prior to word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration 5 min following word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration 10 min following word presentation
Number of subjects: 0
Study 9862412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration for 2 min during the experiment
Number of subjects: 0
Study 9862412 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration
Number of subjects: 0
Study 7638804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised morphine (10 mg)
Number of subjects: 12
Study 7638804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised morphine (25 mg)
Number of subjects: 12
Study 7638804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (1 mg)
Number of subjects: 12
Study 7638804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (2.5 mg)
Number of subjects: 12
Study 7638804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2692816 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5.5 mg of the ethylendiamine salt.kg‐1 intravenously)
Number of subjects: 5
Study 2692816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31508863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg) with paracetamol (1 g)
Number of subjects: 60
Study 31508863 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (1 mg/kg)
Number of subjects: 60
Study 31703247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement (EUHFL and HYPOFL; 10 min ad libitum consumption)
Number of subjects: 12
Study 31703247 — intervention group
Group type: COMPARATOR
Intervention: No fluid replacement (EUHNF and HYPONF)
Number of subjects: 12
Study 31703247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement (HYPOFL)
Number of subjects: 12
Study 27020912 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP sugar‐free chewing gum
Number of subjects: 10
Study 27020912 — intervention group
Group type: COMPARATOR
Intervention: Regular sugar‐free chewing gum without CPP‐ACP
Number of subjects: 10
Study 27020912 — intervention group
Group type: COMPARATOR
Intervention: Saliva-no chewing gum
Number of subjects: 10
Study 25209313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) every 4 weeks
Number of subjects: 787
Study 25209313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) weekly
Number of subjects: 787
Study 25209313 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) twice weekly
Number of subjects: 787
Study 25209313 — intervention group
Group type: COMPARATOR
Intervention: High quality anticoagulation management (HQACM) with venous INR testing every 4 weeks
Number of subjects: 787
Study 23638622 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day) for 12 weeks
Number of subjects: 64
Study 23638622 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study 21205325 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril, 12.5 mg hydrochlorothiazide)
Number of subjects: 216
Study 21205325 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (individual drugs)
Number of subjects: 216
Study 19419544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 70
Study 19419544 — intervention group
Group type: COMPARATOR
Intervention: Traditional antiepileptic drugs
Number of subjects: 70
Study 16968583 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (TRAV; travoprost 0.004%)
Number of subjects: 56
Study 16968583 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%)
Number of subjects: 56
Study 15367414 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocet (M; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Number of subjects: 160
Study 15367414 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (E; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Number of subjects: 160
Study 11967795 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (2-32 mg) over a median period of 84 days (range: 1-418 days)
Number of subjects: 1893
Study 11967795 — intervention group
Group type: COMPARATOR
Intervention: Placebo over a median period of 85 days (range: 1-398 days)
Number of subjects: 1893
Study 9174296 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by propofol 2 mg/kg
Number of subjects: 140
Study 9174296 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by etomidate 0.3 mg/kg
Number of subjects: 140
Study 9174296 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by thiopental 4 mg/kg
Number of subjects: 140
Study 9174296 — intervention group
Group type: COMPARATOR
Intervention: d-tubocurarine 3 mg followed by thiopental 4 mg/kg and succinylcholine 1 mg/kg
Number of subjects: 140
Study 8465885 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone added to fluvoxamine therapy
Number of subjects: 33
Study 8465885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3763655 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg penbutolol and 3 mg piretanide
Number of subjects: 20
Study 3763655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29780062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella (6 g/day)
Number of subjects: 27
Study 29780062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7.2 g/day lactose)
Number of subjects: 27
Study 26807672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenously over 40 min)
Number of subjects: 36
Study 26807672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25264974 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBCARE (12-week fixed, six-lesson behavioral treatment based on cognitive behavioral therapy)
Number of subjects: 289
Study 25264974 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 289
Study 21969363 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 242
Study 21969363 — intervention group
Group type: COMPARATOR
Intervention: Community practice
Number of subjects: 242
Study 19898831 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg subcutaneous)
Number of subjects: 8
Study 19898831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18515527 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE intervention
Number of subjects: 0
Study 18515527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16037172 — intervention group
Group type: EXPERIMENTAL
Intervention: Espocan (ES) 18-gauge modified epidural needle with 27-gauge Pencan atraumatic spinal needle
Number of subjects: 100
Study 16037172 — intervention group
Group type: COMPARATOR
Intervention: Tuohy 18-gauge conventional needle with 27-gauge Gertie Marx atraumatic spinal needle
Number of subjects: 100
Study 12425803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Number of subjects: 147
Study 12425803 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Number of subjects: 147
Study 12425803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Number of subjects: 147
Study 12425803 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Number of subjects: 147
Study 10523330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% fat, 54% carbohydrate)
Number of subjects: 14
Study 10523330 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (45% fat, predominantly saturated fat, 36% carbohydrate)
Number of subjects: 14
Study 7627480 — intervention group
Group type: EXPERIMENTAL
Intervention: Light reflective rheography (LRR)
Number of subjects: 0
Study 7627480 — intervention group
Group type: COMPARATOR
Intervention: Ascending venography
Number of subjects: 0
Study 2034245 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam
Number of subjects: 47
Study 2034245 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 47
Study 2034245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7047341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (400 mg b.i.d.)
Number of subjects: 39
Study 7047341 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g/day)
Number of subjects: 39
Study 7047341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study 7047341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine
Number of subjects: 39
Study 31319053 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120
Study 31319053 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 120
Study 31319053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 120
Study 31319053 — intervention group
Group type: COMPARATOR
Intervention: Control (no sedation mentioned)
Number of subjects: 120
Study 28772131 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-on-the-line group
Number of subjects: 30
Study 28772131 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 30
Study 28772131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 25970543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour ESR1 gene expression
Number of subjects: 344
Study 25970543 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of necrosis
Number of subjects: 344
Study 25970543 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐based Immune Score (mIS) in stage III right‐sided colon cancer
Number of subjects: 344
Study 23361158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU weekly for 12 weeks followed by 50,000 IU every other week for 40 weeks)
Number of subjects: 46
Study 23361158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 1 year)
Number of subjects: 46
Study 21718620 — intervention group
Group type: EXPERIMENTAL
Intervention: Valplast dentures (group A)
Number of subjects: 76
Study 21718620 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable partial dentures (group B)
Number of subjects: 76
Study 21718620 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 76
Study 19390704 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Enalapril (A)
Number of subjects: 72
Study 19390704 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (B)
Number of subjects: 72
Study 17047649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (120 mg/m²) with granulocyte-colony stimulating factor support (PET)
Number of subjects: 200
Study 17047649 — intervention group
Group type: COMPARATOR
Intervention: Tri-weekly epirubicin (90 mg/m²) and paclitaxel (175 mg/m²) (ET)
Number of subjects: 200
Study 17047649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin, epirubicin, and paclitaxel (PET)
Number of subjects: 200
Study 17047649 — intervention group
Group type: COMPARATOR
Intervention: Tri-weekly epirubicin and paclitaxel (ET)
Number of subjects: 200
Study 14723987 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (3 days)
Number of subjects: 5948
Study 14723987 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 5948
Study 14723987 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (1 day)
Number of subjects: 5948
Study 11760527 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 10 s/cc
Number of subjects: 50
Study 11760527 — intervention group
Group type: COMPARATOR
Intervention: Injection speed of 30 s/cc
Number of subjects: 50
Study 9292380 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy
Number of subjects: 0
Study 9292380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8161675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sodium phosphate solution regimen (Fleet Phospho-Soda)
Number of subjects: 52
Study 8161675 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene glycol (PEG)-electrolyte lavage
Number of subjects: 52
Study 8161675 — intervention group
Group type: COMPARATOR
Intervention: PEG lavage
Number of subjects: 52
Study 8161675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate regimen
Number of subjects: 52
Study 3745848 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (100 ml)
Number of subjects: 10
Study 3745848 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (100 ml)
Number of subjects: 10
Study 3745848 — intervention group
Group type: COMPARATOR
Intervention: Sugared water (100 ml)
Number of subjects: 10
Study 3745848 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (50 ml)
Number of subjects: 10
Study 29807719 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist Footwear (MFW)
Number of subjects: 32
Study 29807719 — intervention group
Group type: COMPARATOR
Intervention: Conventional Running Shoes (CRS)
Number of subjects: 32
Study 27181509 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS active (bilateral, 20-min session at 2mA)
Number of subjects: 10
Study 27181509 — intervention group
Group type: COMPARATOR
Intervention: tDCS sham (bilateral, 20-min session)
Number of subjects: 10
Study 24398734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h educational intervention for anesthesia faculty
Number of subjects: 71
Study 23656644 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 429
Study 23656644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 20609130 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) administered intradermally and subcutaneously, 5 units/site, total dose 40-200 units.
Number of subjects: 14
Study 20609130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for 8 patients in randomized trial).
Number of subjects: 14
Study 18990047 — intervention group
Group type: EXPERIMENTAL
Intervention: Active plant (vortex-rotated tap water)
Number of subjects: 50
Study 18990047 — intervention group
Group type: COMPARATOR
Intervention: Control plant (tap water)
Number of subjects: 50
Study 15855884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (estrogen and gestagen)
Number of subjects: 39
Study 14621090 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management intervention (skill-oriented patient education programme and near-home fitness programme, on top of usual care)
Number of subjects: 248
Study 14621090 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management intervention
Number of subjects: 248
Study 14621090 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care by the treating chest physician)
Number of subjects: 248
Study 10806378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone antibiotics (FQ)
Number of subjects: 0
Study 10806378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10806378 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 0
Study 8638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0
Study 8638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates alone or in combination with hydralazine
Number of subjects: 0
Study 8638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of nitrates
Number of subjects: 0
Study 8638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dose regimen of nitrates with hydralazine
Number of subjects: 0
Study 1503483 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FAM (5-FU + ADR + MMC) therapy
Number of subjects: 71
Study 1503483 — intervention group
Group type: COMPARATOR
Intervention: 5-FU mono-therapy
Number of subjects: 71
Study 6476623 — intervention group
Group type: COMPARATOR
Intervention: Intermittent rectal diazepam (0.5 mg/kg every 8 hours during fever)
Number of subjects: 100
Study 6476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenobarbital (BID)
Number of subjects: 100
Study 29533112 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound treatment
Number of subjects: 0